Engineered T Cells Show Promise Against Childhood Cancers in Phase I Trial

This Phase I clinical trial investigated a novel immunotherapy approach for treating aggressive childhood cancers by engineering patients' own T cells to target the GD2 protein found on neuroblastoma, osteosarcoma, and other sarcomas. The study enrolled 15 children and young adults aged 1-35 years whose cancers had failed standard treatments.

Researchers collected T cells from patients through apheresis, then genetically modified them with a third-generation chimeric antigen receptor (CAR) designed to recognize GD2. These CAR-T cells included an innovative safety feature - a molecular suicide switch that could be activated with a drug called AP1903 if dangerous side effects occurred.

Participants first received cyclophosphamide chemotherapy to deplete their existing immune cells, creating space for the engineered T cells to function. They then received escalating doses of CAR-T cells ranging from 100,000 to 10 million cells per kilogram of body weight, following a standard dose-escalation protocol.

The trial's primary goals were establishing manufacturing feasibility and determining safe dosing levels. Secondary objectives included measuring anti-tumor effects, tracking how long the engineered cells persisted in patients' bodies, and testing the safety switch if needed. Patients showing stable disease or partial responses could receive a second treatment cycle at a higher dose.

This completed study represents an important step in developing safer, more effective immunotherapies for childhood cancers. The inclusion of safety switches in CAR-T cell design addresses previous concerns about controlling these powerful treatments, potentially making them safer for pediatric patients whose developing immune systems require extra protection.